1. Home
  2. HMR vs RLYB Comparison

HMR vs RLYB Comparison

Compare HMR & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HMR

Heidmar Maritime Holdings Corp.

HOLD

Current Price

$0.90

Market Cap

49.3M

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$8.25

Market Cap

44.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HMR
RLYB
Founded
1984
2018
Country
Greece
United States
Employees
57
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.3M
44.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
HMR
RLYB
Price
$0.90
$8.25
Analyst Decision
Strong Buy
Hold
Analyst Count
2
2
Target Price
$5.00
N/A
AVG Volume (30 Days)
39.4K
89.8K
Earning Date
03-24-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$858,000.00
Revenue This Year
$64.04
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.00
52 Week Low
$0.76
$0.24
52 Week High
$3.12
$11.49

Technical Indicators

Market Signals
Indicator
HMR
RLYB
Relative Strength Index (RSI) 53.78 51.44
Support Level $0.87 $7.90
Resistance Level $0.96 $9.25
Average True Range (ATR) 0.05 0.50
MACD 0.01 -0.17
Stochastic Oscillator 66.47 29.74

Price Performance

Historical Comparison
HMR
RLYB

About HMR Heidmar Maritime Holdings Corp.

Heidmar Maritime Holdings Corp is an asset-light tanker pool, and commercial and technical management company. The company is a fast-growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. The company has also recently expanded its business to offer pool management of dry bulk vessels and technical management. The company generates maximum revenue from Singapore.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: